Beaver Run Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

Uncovering Mechanisms of Immune-Based Therapy in Cancer and Autoimmunity (B3)

Scientific Organizers: Daniel J. Cua, E. John Wherry and Carla V. Rothlin


February 18—22, 2019

Beaver Run Resort, Breckenridge, Colorado, USA


Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to generous support from an anonymous donor.

Organized in collaboration with Cancer Research UK

Sponsored by AbbVie Inc., BioLegend, Inc., Compass Therapeutics, EMD Serono Research and Development Institute, Inc., Genentech, Inc., Incyte Corporation, MacroGenics, Inc., Merck & Co., Inc., MorphoSys AG, Pfizer Inc., Roche, Surface Oncology, Takeda Pharmaceutical Company Limited and Tessa Therapeutics Ltd.


Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email info@keystonesymposia.org if you are interested.
BEWARE of booking lodging through companies unaffiliated with Keystone Symposia. Click here for more details.

Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.

DEADLINES:
*All deadlines end at 11:59 PM US Mountain Standard Time
Scholarship Deadline: Oct 23, 2018 [details]
Discounted Abstract Deadline: Oct 23, 2018 [details]
Abstract Deadline: Nov 15, 2018 [details]
Discounted Registration Deadline: Dec 18, 2018 [details]

If you have missed a deadline due to the US government shutdown, please contact our office.

Click here to view Cancellation Policy

Register Yourself Deadlines and Fees

Rates and Deadlines listed below are for the 2019-B3 "Uncovering Mechanisms of Immune-Based Therapy in Cancer and Autoimmunity" conference only.

*All deadlines end at 11:59 PM US Mountain Standard Time

Deadline Date Cost
Discounted Abstract Deadline
More details
Before and On October 23, 2018 100.00 USD*
- 50.00 USD discount
Abstract Deadline
More details
After October 23, 2018 until January 7, 2019 100.00 USD*
* 50.00 USD of Abstract fee deducted from your registration fee when you register for this meeting
Scholarship
More details
October 23, 2018 n/a
Discounted NON-STUDENT Registration
More details
Before and On December 18, 2018 845.00 USD
(includes 200.00 discount)
Regular NON-STUDENT Registration
More details
After December 18, 2018 1045.00 USD
Discounted STUDENT Registration
More details
Before and On December 18, 2018 620.00 USD
(includes 200.00 discount)
Regular STUDENT Registration
More details
After December 18, 2018 820.00 USD

* Changes in payment type that result in a refund are subject to a processing fee.
* Currency exchange gains/losses are the responsibility of the registrant and the Keystone Symposia will accept no liability for money loss through bank charges, transfers or currency fluctuations.




Discounted Abstract Deadline: October 23, 2018

*All deadlines end at 11:59 PM US Mountain Standard Time

Abstract Submission Fee: 100.00 USD*
Submission by this date receives 50.00 USD discount.
*50.00 USD will be applied to Registration Fee when you register

Abstract Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadlines. Submitting an abstract does not constitute or guarantee registration.

Submitting your abstract early allows us to:
  • submit your abstract to organizers to be considered for a short talk
  • accept your abstract online
  • include your abstract on our website and in our secure mobile app
  • reserve your space at the meeting for a poster presentation.**
**Submitting an abstract does not constitute or guarantee registration.
(The Abstract Deadline: is November 15, 2018)

Global Health Travel Award Deadline:

*All deadlines end at 11:59 PM US Mountain Standard Time


Global Health Travel Award Details: You MUST complete your Global Health Travel Award appplication by the Global Health Travel Award Deadline and complete the other required steps (verify your contact information and submit a recommendation letter) to be considered for a travel award.


Click here to learn more about Global Health Travel Awards.

Scholarship Deadline: October 23, 2018

*All deadlines end at 11:59 PM US Mountain Standard Time


Scholarship Details: You MUST submit your abstract by the Scholarship Deadline and complete the other required steps (submit a scholarship application and submit a mentor letter) to be considered for a scholarship.

Click here to learn more about Scholarships.

Abstract Deadline: November 15, 2018

*All deadlines end at 11:59 PM US Mountain Standard Time


Abstract Submission Fee: 100.00 USD*
*50.00 USD will be applied to Registration Fee when you register

Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadline. Submitting an abstract does not constitute or guarantee registration.

Submitting your abstract by the Abstract Deadline allows us to:

  • submit your abstract to organizers to be considered for a short talk
  • include your abstract on our website and in our secure mobile app
  • reserve your space at the meeting for a poster presentation.**
**Submitting an abstract does not constitute or guarantee registration.
Abstracts submitted after the Abstract Deadline will NOT be considered for a short talk.

(Discounted Abstract Deadline: is October 23, 2018)

Discounted Registration Deadline: December 18, 2018

*All deadlines end at 11:59 PM US Mountain Standard Time


Registration Fee: 845.00 USD* (includes 200.00 USD discount)
Student Registration Fee: 620.00 USD* (must complete student verification form)

*Includes 50.00 USD of your abstract submission fee

After the Discounted Registration Deadline:


Registration Fee: 1045.00 USD*
Student Registration Fee: 820.00 USD* (must complete student verification form)

*Includes 50.00 USD of your abstract submission fee

Registration spaces are limited and may fill prior to discounted registration deadline.

Please be advised that some meeting participants have received calls and emails from a number of different housing services, including "Exhibitors Housing Services," “Expo Housing Services,” "Global Housing," etc. THESE COMPANIES ARE NOT AFFILIATED WITH KEYSTONE SYMPOSIA and are not authorized by Keystone Symposia to contact you. These companies may tell you that the meeting is filling, without any actual knowledge to that effect, and pressure you into giving them your credit card number to make a lodging reservation with them.

We highly recommend that you not make a reservation with these companies or any other housing service! These companies' representations to participants have been misleading. Please report any calls or correspondence you might have received to Keystone Symposia and book only through lodging links in your Keystone Symposia account, an established travel agency or directly with the hotel(s) listed on our website.
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Monday, February 18 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Friday, February 22 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Saturday, February 23 in order to fully experience the meeting.

MONDAY, FEBRUARY 18

16:00—20:00
Arrival and Registration

Colorado Ballroom Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Colorado Ballroom Foyer

TUESDAY, FEBRUARY 19

07:00—08:00
Breakfast

Summit Gallery
08:00—09:00
Welcome and Keynote Address
Registered attendees can view abstracts starting on 01/18/2019

Colorado Ballroom
* Daniel J. Cua, Merck Research Laboratories, USA

Arlene H. Sharpe, Harvard Medical School, USA
Checkpoint Blockade for Cancer Immunotherapy

09:00—11:15
Checkpoint Blockade Predisposes Patients to Autoimmunity
Registered attendees can view abstracts starting on 01/18/2019

Colorado Ballroom
* E. John Wherry, University of Pennsylvania, USA

Jeffrey A. Bluestone, University of California, San Francisco, USA
Development of Syngeneic NOD Tumor Models to Study Tumor Immunity in Autoimmune-Prone Mice

Coffee Break

Jennifer Ann Wargo, University of Texas MD Anderson Cancer Center, USA
Immune Mechanisms Influencing Checkpoint Therapy

Dario A. A. Vignali, University of Pittsburgh School of Medicine, USA
Regulation of Autoimmunity and Cancer by PD1 and LAG3

Soyoung Oh, Genentech, Inc., USA
Short Talk: PD-L1 Expression by Dendritic Cells Is a Critical Checkpoint in the Regulation of T Cell Immunity

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Breckenridge Ballroom
13:00—22:00
Poster Viewing

Breckenridge Ballroom
16:30—17:00
Coffee Available

Colorado Ballroom Foyer
17:00—19:00
Genetics of Autoimmunity and Cancer: What are the Common Denominators?
Registered attendees can view abstracts starting on 01/18/2019

Colorado Ballroom
* Carla V. Rothlin, Yale University, USA

Alex Marson, University of California, San Francisco, USA
Reprogramming Human Immune Cell Circuitry

Elissa K. Deenick, Garvan Institute of Medical Research, Australia
Signals Controlling Lymphocyte Activation and Autoimmunity - Lessons from Inborn Errors of Immunity

Wenjun Ouyang, Amgen, Inc., USA
Population to Population Strategies to Identify Novel Regulatory Pathways for T Cells

Zia Khan, Genentech, Inc., USA
Short Talk: Genetic Risk for Skin Autoimmunity Impacts the Safety and Efficacy of Immune Checkpoint Blockade in Urothelial Carcinoma

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
19:30—22:00
Poster Session 1

Breckenridge Ballroom

WEDNESDAY, FEBRUARY 20

07:00—08:00
Breakfast

Summit Gallery
08:00—11:00
Cellular Reprogramming: Regulatory vs. Functional Fate
Registered attendees can view abstracts starting on 01/18/2019

Colorado Ballroom
* Susan M. Kaech, The Salk Institute, USA

Alexander Y. Rudensky, HHMI/Memorial Sloan Kettering Cancer Center, USA
Treg Stability in Disease

Mark S. Anderson, University of California, San Francisco, USA
Modulating Self-Tolerance in Autoimmunity and Cancer

Coffee Break

Maria Grazia Roncarolo, Stanford University School of Medicine, USA
Regulatory T Cell Therapy in Cancer and Autoimmunity

Eric Meffre, Yale University School of Medicine, USA
Impaired B Cell Tolerance and Autoimmunity: CTLA-4 Blockade Dirty Secret

Theodore T. Drashansky, University of Florida, USA
Short Talk: Epigenetic Landscape Dictated by Bcl11b Sustains Treg Cell Program while Blocking Innate Lineage and Apoptosis

Sophie Lucas, de Duve Institute, Belgium
Short Talk: Structural Basis of Latent TGF-β1 Presentation and Activation by GARP on Human Regulatory T Cells

11:00—17:00
On Own for Lunch

11:00—13:00
Poster Setup

Breckenridge Ballroom
13:00—22:00
Poster Viewing

Breckenridge Ballroom
14:30—16:30
Workshop 1: Immune Monitoring of Checkpoint Blockade Therapies

Colorado Ballroom
* Soyoung Oh, Genentech, Inc., USA

Peter V. Kharchenko, Harvard Medical School, USA
Molecular Impact of Prostate Cancer Metastasis on the Bone Marrow Microenvironment

Kasey L. Couts, University of Colorado Denver, USA
Differential Gene Expression Across Melanoma Subtypes Predicts Responses to Immune Checkpoint Blockade

Yannick Simoni, Fred Hutchinson Cancer Research Center, USA
Identification of Tumor-Specific CD8+ T Cells in EBV-Driven Lymphoephitelioma-Like Carcinoma: A Case Report

Colt Egelston, City of Hope, USA
Identification of Tumor Inflammation-Associated Exhausted CD8+ T Cells in Breast Cancer Patients

Alexander Huang, University of Pennsylvania, USA
Clinical and Immunologic Activity of a Single Dose of Neoadjuvant PD-1 Blockade and Predictors of Clinical Outcomes in Resectable Melanoma

Debattama Sen, Harvard Medical School, USA
Functionally Specialized Subsets of Exhausted CD8+ T Cells Mediate Tumor Control and Differentially Respond to Checkpoint Blockade

* Krijn Dijkstra, Netherlands Cancer Institute, Netherlands
Generation of Tumor-Reactive T Cells by Co-Culture of Peripheral Blood Lymphocytes and Tumor Organoids

Martina Damo, Yale University, USA
A New Mouse Model to Investigate Tissue-Specific Aspects of Peripheral T Cell Tolerance

16:30—17:00
Coffee Available

Colorado Ballroom Foyer
17:00—19:00
Cellular Reprogramming: CD8 T Cell Exhaustion and CD4 T Cell Lineages
Registered attendees can view abstracts starting on 01/18/2019

Colorado Ballroom
* Dario A. A. Vignali, University of Pittsburgh School of Medicine, USA

E. John Wherry, University of Pennsylvania, USA
T Cell Exhaustion and Fate Decisions – Implications for Immunotherapy

Ian A. Parish, Peter MacCallum Cancer Centre, Australia
Phenotypically and Functionally Defining CD8+ T Cell Tolerance versus Exhaustion

W. Nicholas Haining, Dana-Farber Cancer Institute, USA
Epigenetic Engineering of Tumor Immunity

Shin Foong Ngiow, University of Pennsylvania, USA
Short Talk: Lag3 Represses Cytotoxicity Program to Facilitate CD8 T Cell Exhaustion

Kristen Elaine Pauken, Harvard Medical School, USA
Short Talk: Deletion of PD-1 Promotes Anti-Tumor Immunity through Cell Intrinsic and Extrinsic Improvements in CD8+ T Cell Metabolism and Functions

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
19:30—22:00
Poster Session 2

Breckenridge Ballroom

THURSDAY, FEBRUARY 21

07:00—08:00
Breakfast

Summit Gallery
08:00—11:00
Macrophage Biology, Tissue Repair, Autoimmunity and Cancer
Registered attendees can view abstracts starting on 01/18/2019

Colorado Ballroom
* Catherine Hedrick, La Jolla Institute for Allergy and Immunology, USA

Mikael J. Pittet, Massachusetts General Hospital, USA
Myeloid Cells in Cancer Therapies

Carla V. Rothlin, Yale University, USA
Coincidence Detectors in Macrophages and Tissue Repair

Coffee Break

Ming O. Li, Memorial Sloan Kettering Cancer Center, USA
Deconstructing the Antigen-Presenting Cell Compartment in Cancer

Nathaniel R. West, Genentech, Inc., USA
Host Genetics, Cytokines, and Dysbiosis in the Regulation of Chronic Intestinal Inflammation and Cancer

Hind Medyouf, Institute for Tumor Biology and Experimental Therapy, Germany
Short Talk: Targeting TAM Receptors Unleashes Anti-Leukemic Immunity and Enables Checkpoint Blockade Leading to Eradication of Leukemic Cells

Sergei Grivennikov, Fox Chase Cancer Center, USA
Short Talk: Cell Type Specific Role of Cytokines in Control of Tumor Promoting Inflammation and Tumor Bacterial Invasion

11:00—17:00
On Own for Lunch

11:00—13:00
Poster Setup

Breckenridge Ballroom
13:00—22:00
Poster Viewing

Breckenridge Ballroom
14:30—16:30
Workshop 2: Latest Developments on the Role of Myeloid Cells in Inflammation and Cancer

Colorado Ballroom
* Hind Medyouf, Institute for Tumor Biology and Experimental Therapy, Germany

Yemsratch T. Akalu, Yale University School of Medicine, USA
An eMERerging Target in Cancer Immunotherapy

Joanne Tan, Arcus Biosciences, USA
Targeting Innate Immune Cells for the Treatment of Cancer

Tal Burstyn-Cohen, Hebrew University Jerusalem, Israel
Myeloid-Derived PROS1 Inhibits Tumor Metastasis by Curbing Inflammation

Chang-Yu Chen, Tokyo University of Science, Japan
An Alarmin HMGN1 Synergizes with PD-L1 Blockade and CD4 Depletion to Reinforce CD8 T Cell-Mediated Anti-Tumor Immunity

* Kelsey Sivick Gauthier, Aduro Biotech, Inc., USA
Magnitude of Therapeutic STING Activation Critically Impacts CD8+ T Cell-Mediated Anti-Tumor Immunity

Karen Hastings, University of Arizona College of Medicine, USA
High GILT Expression and an Active and Functional MHC Class II Antigen Presentation Pathway Are Associated with Improved Survival in Melanoma

Emma Lo Kuan, Benaroya Research Institute, USA
Thymic Stromal Lymphopoietin Promotes Interplay between Tumor Cells, Myeloid Cells, and CD8+ T Cells in Regulation of Breast Cancer

Rachel S. Friedman, National Jewish Health and University of Colorado Denver, USA
Mononuclear Phagocytes Drive a Mertk-Dependent Tolerance Checkpoint at the Autoimmune Disease Site

16:30—17:00
Coffee Available

Colorado Ballroom Foyer
17:00—19:30
Neutrophils and MDSCs in Host Defense and Cancer
Registered attendees can view abstracts starting on 01/18/2019

Colorado Ballroom
* Carla V. Rothlin, Yale University, USA

Matthew F. Krummel, University of California, San Francisco, USA
Archetypes of Immunity and Myeloid Tuning Immunotherapies

Catherine Hedrick, La Jolla Institute for Allergy and Immunology, USA
Neutrophil Heterogeneity in Cancer

Susan M. Kaech, The Salk Institute, USA
Nutrient Regulation of Anti-Tumor Immunity

Dmitry I. Gabrilovich, Wistar Institute, USA
Neutrophils and PMN-MDSC in Cancer: Two Sides of Functional Diversity

James T. Nevin, University of Connecticut Health Center, USA
Short Talk: Sympathetic Nervous Tone Influences Accumulation of Myeloid-Derived Suppressor Cells and Immune Control of Tumor Growth

Eynav Klechevsky, Washington University School of Medicine, USA
Short Talk: Upstream Regulation of Autoimmunity and Cancer via Human Dendritic Cell Subsets

19:30—20:30
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
19:30—22:00
Poster Session 3

Breckenridge Ballroom

FRIDAY, FEBRUARY 22

07:00—08:00
Breakfast

Summit Gallery
08:00—11:00
Finding the Cure for Cancer
Registered attendees can view abstracts starting on 01/18/2019

Colorado Ballroom
* Daniel J. Cua, Merck Research Laboratories, USA

Drew M. Pardoll, Johns Hopkins University School of Medicine, USA
Checkpoint Inhibition

Alan J. Korman, Bristol-Myers Squibb, USA
An Acidic pH Selective Pathway for Immune Regulation

Coffee Break

Emmett V. Schmidt, Merck Research Labs, USA
Developing Combination Strategies using PD-1 Checkpoint Inhibitors to Treat Cancer

Robert L. Coffman, Dynavax Technologies, USA
Expanding the Potential of Cancer Immunotherapy with TLR9 Agonists

Leonardo Ferreira, University of California, San Francisco, USA
Short Talk: Chimeric Antigen Receptors for Dissecting Treg Biology and Next-Gen Treg Therapy

Lisa Cucolo, University of Pennsylvania, USA
Short Talk: Tumor RIPK1 Signaling Mediates Intrinsic and Extrinsic Mechanisms of Resistance to Immune Checkpoint Blockade Therapy

11:00—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Colorado Ballroom Foyer
17:00—18:45
Integrated Themes across Preclinical and Clinical Treatment of Cancer and Autoimmunity
Registered attendees can view abstracts starting on 01/18/2019

Colorado Ballroom
* Maria Grazia Roncarolo, Stanford University School of Medicine, USA

Mark J. Smyth, QIMR Berghofer Medical Research Institute, Australia
The Role of CD39 in the Immunological Control of Cancer

Daniel J. Cua, Merck Research Laboratories, USA
Applying Lessons from Autoimmune Inflammation to Immuno-Oncology

Hergen Spits, University of Amsterdam, Netherlands
Anti-Tumor B Cell Responses in Cancer Patients Responding to Immunotherapy

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions
Registered attendees can view abstracts starting on 01/18/2019

Colorado Ballroom
* Hergen Spits, University of Amsterdam, Netherlands

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Breckenridge Ballroom

SATURDAY, FEBRUARY 23

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

AbbVie Inc. BioLegend, Inc.
Organized in collaboration with Cancer Research UK Compass Therapeutics
EMD Serono Research and Development Institute, Inc. Genentech, Inc.
Incyte Corporation MacroGenics, Inc.
Merck & Co., Inc. MorphoSys AG
Pfizer Inc. Roche
Surface Oncology Takeda Pharmaceutical Company Limited
Tessa Therapeutics Ltd.
 

We gratefully acknowledge additional support from these exhibitors at this conference:

AYOXXA Biosystems GmbH
Please stop by to meet these exhibitors during the conference.


We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1 R13 CA232437-01

Funding for this conference was made possible (in part) by 1 R13 CA232437-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional support for this conference from:

American Society of Gene & Cell Therapy (ASGCT) eLife

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Dynavax Technologies Corporation


Genentech, Inc.


Merck & Co., Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676